Common viral respiratory infections such as COVID-19, respiratory syncytial virus (RSV) and influenza are linked to an ...

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

Frailty strongly predicts worse RSV outcomes in older adults, highlighting the need for targeted care as aging populations ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...